Results 61 to 70 of about 12,890,416 (254)

Design of a retrospective patient record study on the occurrence of adverse events among patients in Dutch hospitals [PDF]

, 2009
Background: Various international studies have shown that a substantial number of patients suffer from injuries or even die as a result of care delivered in hospitals.
van der Wal Gerrit, Bruijne, M.C. de, Maurits W van Tulder, Asscheman Henk, van Tulder Maurits W, Waaijman, Roelof, Waaijman, R., de Bruijne, M.C., Asscheman, Henk, van der Wal, Gerrit, Zegers Marieke, Hoonhout, L.H.F., Peter Spreeuwenberg, Spreeuwenberg, Peter, Tulder, M.W. van, van der Wal, G., Wal, Gerrit van der, de Bruijne, Martine C., Marieke Zegers, Hoonhout Lilian HF, Lilian HF Hoonhout, Cordula Wagner, Wal, G. van der, Wagner, C., van Tulder, M.W., Wagner, Cordula, Zegers, H.W.M., Gerrit van der Wal, Martine C de Bruijne, Henk Asscheman, Groenewegen, Peter P., Spreeuwenberg Peter, de Bruijne Martine C, Zegers, M., Roelof Waaijman, Wagner Cordula, Spreeuwenberg, P., van Tulder, Maurits W., Hoonhout, Lilian H. F., Waaijman Roelof, Zegers, Marieke, Asscheman, H., Bruijne, Martine C. de, van Tulder, M.W.; id_orcid   +43 more
core   +4 more sources

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

Frontiers in Immunology
Immune checkpoint inhibitors (ICIs) are specialized monoclonal antibodies (mAbs) that target immune checkpoints and their ligands, counteracting cancer cell-induced T-cell suppression.
Wonyoung Jo, Taejoon Won, Abdel Daoud, Daniela Čiháková, Daniela Čiháková   +4 more
doaj   +1 more source

Immune-Related Adverse Events: A Case-Based Approach

Frontiers in Oncology, 2019
Immunotherapy has heralded the advent of a new era in oncology. Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune system to fight cancer.
Caoilfhionn Connolly, Kalindi Bambhania, Jarushka Naidoo, Jarushka Naidoo   +3 more
doaj   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events [PDF]

, 2009
Epidemiological evidence has suggested a link between beta(2)-agonists and increased asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta(2)-agonists are safe ...
Christopher J Cates, Jaeschke, R, Lasserson, TJ, Roman Jaeschke, Toby J Lasserson, Cates, CJ   +5 more
core   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor

DEN Open, 2022
Case: A 66‐year‐old man started carboplatin + etoposide + atezolizumab therapy for advanced small cell lung cancer. Seventeen days after the start of treatment, the patient presented with hematemesis and underwent emergency endoscopy, which revealed ...
Keita Saito, Hironobu Nagumo, Miyuki Iwasaki, Takuro Nishiwaki, Daiki Ozono, Shin Inoue, Souhei Yoshimura, Hideyuki Kishita, Kenichiro Nakachi, Hisato Harasawa, Natsuki Kawamitsu, Shigenobu Yoshimura, Toshiyasu Shiratori, So Nakaji, Hiroyuki Ito   +14 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source